InsidersTradesSigma
Track the ELI LILLY & Co share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, ELI LILLY & Co has recorded 732 reports. Market capitalisation: €1,052.4bn. The latest transaction was reported on 18 August 2026 (Attribution). Among the most active insiders: LILLY ENDOWMENT INC. All data is free.
732
Insider Decl.
n/a
Thresholds
€4m
11 ops.
Buy Volume
€3bn
225 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate ELI LILLY & Co Buy (bullish), based on 27 analysts. Average price target: US$1,299.01.
44Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,706 of 29,062 companies
59.8
score / 100
Value32
Quality87
FCF yld0.6%
Earn yld1.9%
EV/EBITDA31.2x
ROE102%
Gross mgn96%
Net mgn32%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 August 2026
Declarations732 total
8.382 shares@ US$1,183.160.0000% mcap0.8% of flowCommon StockSEC:0000059478-26-000085:0
13.453 shares@ US$1,183.160.0000% mcap1.6% of flowCommon StockSEC:0000059478-26-000087:0
4.191 shares@ US$1,183.160.0000% mcap0.7% of flowCommon StockSEC:0001262388-26-000016:0
6,500 shares@ US$1,175.100.0007% mcap25.1% of flowCommon StockSEC:0001786054-26-000006:0
10.495 shares@ US$1,183.16Common StockSEC:0001310215-26-000015:0
2,000 shares@ US$1,185.010.0002% mcap15.6% of flowCommon StockSEC:0000059478-26-000083:0
5,000 shares@ US$1,190.000.0006% mcap13.5% of flowCommon StockSEC:0001685556-26-000006:0
10,000 shares@ US$1,190.000.0011% mcap31.1% of flowCOMMONSEC144:0001949846-26-000477
981 shares0Common StockSEC:0002032089-26-000002:0
438.707 shares@ US$1,148.840.0000% mcap100.0% of flowCommon StockSEC:0002032089-26-000002:1
13.878 shares@ US$1,146.900.0000% mcap1.6% of flowCommon StockSEC:0000059478-26-000068:0
10.826 shares@ US$1,146.900.0000% mcap0.7% of flowCommon StockSEC:0001310215-26-000013:0
8.647 shares@ US$1,146.900.0000% mcap0.8% of flowCommon StockSEC:0000059478-26-000066:0
4.323 shares@ US$1,146.900.0000% mcap0.8% of flowCommon StockSEC:0001262388-26-000014:0
8.781 sharesCommon StockSEC:0000059478-26-000057:0
14.094 sharesCommon StockSEC:0000059478-26-000059:0
4.39 sharesCommon StockSEC:0001262388-26-000012:0
10.995 sharesCommon StockSEC:0001310215-26-000011:0
2,500 sharesCommon StockSEC:0001826001-26-000006:0
2,500 shares@ US$1,150.770.0003% mcap13.6% of flowCOMMONSEC144:0001949846-26-000366
10.78 shares@ US$919.900.0000% mcap1.0% of flowCommon StockSEC:0000059478-26-000036:0
17.303 shares@ US$919.900.0000% mcap1.5% of flowCommon StockSEC:0000059478-26-000038:0
5.39 shares@ US$919.900.0000% mcap0.7% of flowCommon StockSEC:0001262388-26-000008:0
13.498 shares@ US$919.900.0000% mcap0.9% of flowCommon StockSEC:0000059478-26-000034:0
10.026 shares@ US$989.120.8% of flowCommon StockSEC:0000059478-26-000023:0
25 of 732 declarations
关于 ELI LILLY & Co
礼来公司（Eli Lilly and Company，纽约证券交易所代码：LLY）是一家在美国上市的主要制药公司，总部位于美国印第安纳州印第安纳波利斯。该公司起源于1876年，当时Eli Lilly上校在印第安纳波利斯创立了一家药品制造企业；礼来公司随后于1901年在印第安纳州注册成立，以继承该企业。如今，礼来公司在一个单一的运营部门报告：人类药品。其商业模式围绕创新药物的研发、制造和全球商业化而建立。（[investor.lilly.com](https://investor.lilly.com/static-files/84711071-9e5a-47e1-bc74-d0753a2d93a8)) 从股权分析的角度来看，礼来公司的产品组合目前以心血管代谢增长引擎为主导，同时在肿瘤学、免疫学和其他专业治疗领域也保持着重要的市场份额。主要上市产品包括Mounjaro和Zepbound，它们已成为核心增长动力，此外还有Trulicity、Humalog、Verzenio、Taltz、通过合作推出的Jardiance、Jaypirca以及其他资产。该公司的研发管线也受到密切关注，特别是orforglipron，其口服GLP-1候选药物已成为业内最具战略意义的项目之一。（[investor.lilly.com](https://investor.lilly.com/static-files/84711071-9e5a-47e1-bc74-d0753a2d93a8)) 在竞争方面，礼来公司是基于肠促胰素疗法的全球领导者之一，与诺和诺德（Novo Nordisk）及其他制药同行在一个竞争激烈的市场中展开竞争。其竞争优势来自于强大的临床执行力、广泛的后期研发管线、生产规模以及使其能够在糖尿病和肥胖症领域获得巨大需求的商业足迹。礼来公司2024年年度报告显示，Mounjaro、Trulicity和Zepbound合计占总收入的很大一部分，这突显了心血管代谢特许经营权对投资案例的核心地位。（[investor.lilly.com](https://investor.lilly.com/static-files/84711071-9e5a-47e1-bc74-d0753a2d93a8)) 从地理上看，礼来公司在全球范围内开展业务，在美国和美国以外地区均有销售，并持续投资于主要发达市场和选定的高增长区域。近期公司新闻强化了增长叙事：在2025年和2026年，礼来公司报告了orforglipron的多个积极临床和监管里程碑，Zepbound的扩大准入和定价计划，以及Jaypirca的适应症扩展进展。总而言之，这些发展支持了礼来公司作为一家拥有长期增长动力、强大创新势头以及在全球代谢医学领域日益重要地位的优质大型医疗保健特许经营企业的观点。（[investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-most-prescribed-weight-management?utm_source=openai))
